Leading pharma Sanofi launches multiple sclerosis drug
Sanofi Genzyme, the global business unit of pharma major, Sanofi, has launched Aubagio.
This is a drug to treat multiple sclerosis (MS). MS is a chronic and debilitating disease of the nervous system. It has a range of symptoms like weakness in the limbs, poor vision, fatigue or slurred speech.
Aubagio is the first original once-a-day, oral disease modifying therapy (DMT) for MS in India. It claims to offer an effective, safe and convenient option.
This is a first-line treatment for relapsing forms of MS that has to be taken once a day, with or without food.
There are around two lakh people in India living with MS. New cases are being detected due to greater awareness and access to better diagnostic facilities.
Sanofi claims that when taken daily, Aubagio has shown consistent efficacy in reducing the frequency of relapses, delaying the progression of physical disability and, stopping further decrease in brain volume.
Multiple sclerosis is an autoimmune, debilitating disease of the nervous system that affects the spinal cord and brain. In MS, there is progressive damage to the cover that protects nerve cells, affecting communication between the brain and the nervous system.
Signs include weakness and numbness in the limbs, poor vision, tingling and pain in parts of the body, unsteady walk,